Wall Street researchers just used Claude to design a drug. The experiment has spawned a new investment thesis.

Reported by MarketWatch · Published 21 Oct 2026, 3:35 AM MYT (1 hr ago)

Image: MarketWatch

For years, artificial-intelligence evangelists have boasted about the technology’s capacity to revolutionize drug development and medical research.

Source & full coverage: this summary is aggregated from MarketWatch, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at MarketWatch →

Wall Street researchers just used Claude to design a drug. The experiment has spawned a new investment thesis.

Summary

More in Markets

Netflix vows to revive viewership trends, but investors hit ‘sell’ on the stock

Bull markets tend to peak with a whimper, not a bang — but a 15% correction for the S&P 500 may be next

The Social Security Administration corrected millions of records, and says there’s more to fix

Here’s what matters most to Tesla investors heading into earnings

Investors’ search for safety has made toothpaste stocks more expensive than tech

It’s not just California’s billionaire tax. Wealth is on the ballot in the midterm elections.